image

Meeting Pipeline

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Targeted Protein Degradation
NX-2127 Degrader BTK + IKZF (Oral) B-cell malignancies

 

NX-5948 Degrader BTK (Oral) B-cell malignancies

 

NX-0479 / GS-6791 Degrader IRAK4 (Oral) Rheumatoid arthritis and other inflammatory diseases

 

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Targeted Protein Elevation
NX-1607 Inhibitor CBL-B (Oral) Immuno-oncology

 

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Discovery Pipeline
Wholly Owned 5 targets Undisclosed

 

Gilead Sciences 4 Targets Undisclosed

 

Sanofi 5 Targets Undisclosed

 

Targeted Protein Degradation
NX-2127 DegraderBTK + IKZF (Oral) - B-cell malignancies

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

NX-5948 DegraderBTK (Oral) - B-cell malignancies

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

NX-0479 / GS-6791 DegraderIRAK4 (Oral) - Rheumatoid arthritis and other inflammatory diseases

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Targeted Protein Elevation
NX-1607 InhibitorCBL-B (Oral) - Immuno-oncology

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Discovery Pipeline
Wholly Owned 5 targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Gilead Sciences4 Targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Sanofi5 Targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b